Onechain immunotherapeutics
Web11. jan 2024. · OneChain Immunotherapeutics: ClinicalTrials.gov Identifier: NCT05679895 Other Study ID Numbers: OC-01-21001 : First Posted: January 11, 2024 Key Record Dates: Last Update Posted: February 14, 2024 Last Verified: February 2024 Layout table for additional information; Studies a U.S. FDA-regulated Drug Product: ... Web20. jul 2024. · OneChain Immunotherapeutics General Information. Description. Developer of biomedicines designed to develop immunotherapies against haematological …
Onechain immunotherapeutics
Did you know?
WebEl portal de Agrupaciones Empresariales Innovadoras (AEI) recoge todas las iniciativas de la Dirección General de Industria y de la PYME para el apoyo a los clusters innovadores. El apoyo a la creación y fortalecimiento de clusters forma parte de la estrategia europea de promoción de la competitividad de las pymes y de la innovación WebOneChain Immunotherapeutics (OCI), was founded by the Josep Carreras Leukaemia Research Institute, ICREA, and Dr. Pablo Menéndez in Barcelona in June 2024. …
WebASEBIO · DIEGO DE LEÓN, Nº 49, 1º IZQDA, 28006 MADRID (ESPAÑA) TEL: +34 91 210 93 10 / 74. FAX: +34 91 250 00 63. [email protected] WebOneChain Immunotherapeutics is a spin-off company from the Josep Carreras Leukemia Research Institute and ICREA, based on research led by Dr. Pablo Menéndez's team. …
WebMeet the women of the OneChain team! 👩🔬 Now, it’s Wilmar Castillo Avila’s turn! 💼 Wilmar has a PhD in Biomedicine and works as a project manager in… OneChain … WebThis spin-off, called OneChain Immunotherapeutics (OCI), was founded by the Josep Carreras Leukaemia Research Institute, ICREA, and Dr. Pablo Menéndez in Barcelona …
WebGreat news to end the year! 🥳 Our product OC_1 has reached the clinical phase! 🏥 The Agencia Española de Medicamentos y Productos Sanitarios has approved…
WebOneChain Immunotherapeutics is a spin-off company from the Josep Carreras Leukemia Research Institute and ICREA, based on research led by Dr. Pablo Menéndez. OneChain aims to develop immunotherapies against haematological neoplasms using CAR-T candidates against different antigens. thaillyWebOneChain Immunotherapeutics is a spin-off company of the Josep Carreras Leukemia Research Institute and ICREA, which aims to develop CAR-T candidates against different antigens as a treatment against hematological neoplasms, based on the research of Dr. Pablo Menéndez. Based in Barcelona Tags Biotechnology, Life Science, Medical Total … thail james bond buchtWebOneChain Immunotherapeutics OneChain Immunotherapeutics. Contacto. Información de contacto. OneChain Immunotherapeutics. Jorge Alemany, CEO. [email protected]. C/ Muntaner 383, 3º 2ª ... sync only checked songs and videosWeb27. jul 2024. · OneChain Immunotherapeutics has raised a total of €3.1M in funding over 1 round. This was a Seed round raised on Jul 27, 2024. OneChain Immunotherapeutics … sync-on-greenWebOneChain Immunotherapeutics 1 año 7 meses Senior Scientist jul. de 2024 - actualidad2 meses Barcelona, Catalonia, Spain Scientist feb. de 2024 - actualidad1 año 7 meses Barcelona, Catalonia,... thaillande en aoutWebOneChain Immunotherapeutics S.L (OCI) es una nueva y dinámica spin-off de la Fundación Josep Carreras con la inversión también de Invivo Ventures y CDTI-Innvierte … syncon management calgaryWebOneChain Immunotherapeutics (OCI), was founded by the Josep Carreras Leukaemia Research Institute, ICREA, and Dr. Pablo Menéndez in Barcelona in June 2024. Investors: we tracked 3 investors You need an account to access this feature. Log in or create one from here. Do you have a question? Talk to us. values in USD Investments 3.53M synconise web hosting site